雷替曲塞联合奥沙利铂在晚期大肠癌患者中的应用效果

Application effect of raltitrexed combined with oxaliplatin in patients with advanced colorectal cancer

目的探讨雷替曲塞联合奥沙利铂在晚期大肠癌患者中的应用效果。方法依据治疗方法的不同将90例大肠癌患者分为对照组和观察组,每组45例,对照组患者给予奥沙利铂+氟尿嘧啶化疗,观察组患者给予奥沙利铂+氟尿嘧啶+雷替曲塞化疗。比较两组患者的临床疗效、肿瘤标志物[癌胚抗原(CEA)、糖类抗原19-9(CA19-9)]水平、功能状态[卡氏功能状态(KPS)评分]和不良反应发生情况。结果治疗后,观察组患者的治疗总有效率为57.78%,高于对照组患者的28.89%,差异有统计学意义(P﹤0.05)。治疗后,两组患者CEA、CA19-9水平均低于本组治疗前,且观察组患者CEA、CA19-9水平均低于对照组,差异均有统计学意义(P﹤0.05)。治疗后,观察组患者的KPS评分总改善率为82.22%,明显高于对照组患者的51.11%,差异有统计学意义(P﹤0.01)。治疗后,对照组患者的不良反应总发生率为75.56%,高于观察组患者的55.56%,差异有统计学意义(P﹤0.05)。结论雷替曲塞联合奥沙利铂可有效降低大肠癌患者血清肿瘤标志物水平,降低不良反应发生率,提高临床疗效并改善患者的功能状态。

Objective To investigate the effect of raltitrexed combined with oxaliplatin in patients with advanced colorectal cancer.Method According to different treatment methods,90 patients with colorectal cancer were divided into control group and observation group,45 cases in each group.The control group was given oxaliplatin+fluorouracil chemotherapy,and the observation group was given oxaliplatin+fluorouracil+raltitrexed chemotherapy.The clinical efficacy,tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9)]levels,functional status[Karnofsky performance status(KPS)score]and adverse reactions were compared between the two groups of patients.Result After treatment,the total effective rate of patients in the observation group was 57.78%,which was higher than 28.89%in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of CEA and CA19-9 in the two groups were lower than those before treatment,and the levels of CEA and CA19-9 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the total improvement rate of KPS score in the observation group was 82.22%,which was significantly higher than 51.11%in the control group,and the difference was statistically significant(P<0.05).After treatment,the total incidence of adverse reactions in the control group was 75.56%,which was higher than 55.56%in the observation group,and the difference was statistically significant(P<0.05).Conclusion Raltitrexed combined with oxaliplatin can effectively reduce serum tumor marker levels in patients with colorectal cancer,reduce the incidence of adverse reactions,improve clinical efficacy and improve the functional status of patients.